Jo Shorthouse
Interim Editor of In Vivo
Jo Shorthouse has contributed to various Citeline publications, starting with Scrip in 2008. She has previously edited Scrip Good Clinical Practice, Scrip Clinical Research and the Scrip 100, been a managing editor on Pharma Intelligence commercial team, and most recently turned her hand to freelance health care journalism and editorial consultancy. Jo has a wide-ranging knowledge of many aspects of the pharmaceutical industry which allows her to bring insights to the Citeline and In Vivo teams.
Latest From Jo Shorthouse
How To Develop A Patient-First Strategy For CGT Commercialization
Many new drug commercialization decisions need to happen early in the clinical development of a therapy, and cell and gene treatments are no different. As Amerisource Bergen’s Lung-I Cheng tells In Vivo, creating a patient-first blueprint is the best place to start.
Deals Of The Year 2022 Winners Revealed
For In Vivo's 15th annual Deals of the Year contest, we selected 15 nominees in three categories – Top Alliance, Top Financing and Top M&A. The polls are closed, and it is time to reveal the winners.
The Mandate To Make A Digital Difference
Diogo Rau, chief information and digital officer at Lilly, talks to In Vivo about the company’s plans for making big and disruptive changes using digital strategy to speed up drug development.
Panthera On The SMO Model, Responsible Growth Priorities And The Hybridized Trial Of The Future
In this episode of the In Vivo podcast, Jo Shorthouse speaks with the co-founder and chief commercial officer of the site management organization, Panthera Biopartners. The discussion centers on the practicalities and reality of running clinical trial sites as a business, and the age-old challenge of patient recruitment.
In Vivo’s Deals Of The Year: Cast Your Vote!
It is time for In Vivo's 15th annual Deals of the Year contest. We've selected 15 nominees across three categories – Top Alliance, Top Financing and Top M&A – and you get to pick the winners.
Outlook 2023: The Pharma Rollercoaster Shows No Signs Of Slowing Down
What will 2023 bring as the industry faces one of the toughest periods in the last decade? In Vivo asked three industry experts for their views.